MapLight Therapeutics, Inc.
MPLTMapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system (CNS) disorders.
Earnings
Next report
Sep 18, 2026 (In 3 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system (CNS) disorders. The company utilizes a proprietary discovery platform integrating optogenetics and transcriptomics to identify neural circuits causally linked to disease and target them for therapeutic modulation. Its lead programs target high-unmet-need conditions including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.
A clinical-stage innovator utilizing a differentiated circuit-based discovery platform to develop muscarinic agonists and other CNS therapies with improved tolerability profiles.
FAQ
- What is MapLight Therapeutics, Inc.'s market cap?
- MapLight Therapeutics, Inc. (MPLT) has a market capitalization of $596.4M and trades on NASDAQ.
- Who are MapLight Therapeutics, Inc.'s competitors?
- MapLight Therapeutics, Inc.'s key competitors include Neumora Therapeutics, Inc., Acadia Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., and others. These companies compete in similar markets and product categories.
- Who does MapLight Therapeutics, Inc. partner with?
- MapLight Therapeutics, Inc.'s notable partners include NeuroSolis, Inc..
- Where is MapLight Therapeutics, Inc. headquartered?
- MapLight Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2025.